Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age

View Full Paper
Ask AI
Bookmark
Share

Authors

ZSZeeshan SattarLSLeyla ShuneMMMuhammad Umair Mushtaq

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds melphalan auto-HCT improves survival rates in patients over 70, highlighting key risks for older adults.

Key Points

  • Survival rates at 24 months showed overall survival at 87.8% and disease-free survival at 69.3%.
  • Higher Karnofsky performance status was significantly associated with better overall survival outcomes (HR 1.46, p = 0.046).
  • Autologous hematopoietic cell transplantation allows treatment of multiple myeloma in older adults effectively with manageable risks.
  • Overall, this data emphasizes comprehensive risk assessment beyond age for hematopoietic cell transplantation decisions.

Cite This Study

Sattar et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db5dhttps://doi.org/10.1182/blood-2025-5985
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients2025
  2. 2Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.2025
  3. 3Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide2025
  4. 4Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.2025
  5. 5Chronological age predicts suboptimal multiple myeloma treatment independent of frailty and socioenvironmental factors: A retrospective multi-center cohort study2025